INTRODUCTION
The prevalence of isolated calf vein thrombosis (ICVT) is 5 to 12% in symptomatic patients [1] and asymptomatic ICVT may occurin 15% of patients after total hip and total knee arthroplasty (TKA) [2] . However, treatment of ICVT is still controversial.
Generally, ICVT is not considered to be a source of fatal pulmonary embolism (PE) because the severity of PE depends on the size of the emboli or cardiopulmonary function [3] . However, some authors who recommend anticoagulation therapy are concerned that untreated ICVT may extend to proximal deep veins, which is more likely to result in PE [4] . One patient with May-Thurner syndrome previously underwent catheter-directed thrombolytic therapy with left iliac vein stenting and the other had ICVT after previous contralateral total knee arthroplasty (TKA). This study aimed to investigate short-term treatment outcomes (e.g., proximal thrombus propagation and incidence of PE) in patients with ICVT after TKA according to whether or not they were treated with anticoagulation therapies. were not. Among group II, however, 11 patients received short-term (3 to 7 days) LMWH during admission and 15 patients received antiplatelet therapy for 3 to 6 months.
METHODS
Neither anticoagulation nor antiplatelet agent was administered for 4 patients.
Sixteen patients had concomitant PE and all were asymptomatic. All belonged to group I, except 1 patient who discontinued anticoagulation due to hematemesis one day after anticoagulation therapy.
CT was performed using a Light Speed 16 CT scanner (GE Healthcare, Milwaukee, WI, USA) or Aquilion 64 CT scanner (Toshiba Medical Systems Co., Tokyo, Japan). The contrast media (Optiray 320, Tyco Healthcare, Mallinkrodt, Saint Louis, MO, USA) with a volume of 140 mL was administered through an antecubital vein using an automated power injector at a rate of 3 to 4 mL/sec and was followed a 30 mL saline chaser with the same infusion rate.
Individual contrast optimization was achieved using bolus tracking within the main pulmonary artery. CT pulmonary arteriography was obtained during a shallow inspiratory breathhold in a craniocaudal direction from the aortic arch to the heart base. At 180 seconds after injection of the contrast agent, CT venography was performed from the heart base down to the feet in the craniocaudal direction.
RESULTS
Patient mean age was 68 years (range, 48 to 86 years) and 95% were female. Two patients had bilateral ICVT and 1 patient had a contralateral proximal DVT. Sixteen patients had a concomitant PE and all were asymptomatic. The risk factors for VTE are shown in Table 1 . Two patients had a previous episode of ICVT of the contralateral limb after thesurgery.or.kr (Fig. 1) . In the conservative treatment group, ICVT also disappeared on follow-up DVT-CT and there was no newly developed PE (Fig. 2) .
DISCUSSION
There were many reports on ICVT, but its clinical implication and treatment remains controversial. Traditionally, main concerns in DVT treatment are the risk of PE and post-thrombotic syndrome.
There were autopsy studies demonstrating that ICVT was a source of fatal PE [5, 6] . Sevitt and Gallagher [5] performed autopsies in 74 fatal cases of PE and the rate of fatal PE from ICVT was 15% (11/74). In another autopsy study of 23 patients who died of PE, ICVT was detected in 3 patients (13%) [6] . Although the reported incidence of PE in patients with ICVT range from 7 to 50% [3, [7] [8] [9] , fatal PE caused by ICVT is rarely reported in clinical studies.
However, 20 to 50% of untreated proximal DVT results in significant PE and 5% of such PE are fatal [10] . Therefore, another issue of ICVT is its propagation to the level of or above the popliteal vein.
Based on serial duplex scans of 192 patients with ICVT, Lohr et al. [11] reported that 28% had propagation of their Masuda et al. [16] reported that proximal propagation of ICVT developed in 4% of the cases within 2 weeks of diagnosis and clinically overt PE did not occur regardless of Considering most thrombus propagations occur in the early period, it is reasonable that short-term anticoagulation may be adopted for patients with ICVT. There was a report that short-term anticoagulation in IMCVT is useful to prevent VTE complications [19] , but it was not proven in a prospective randomized study [20] . The authors compared treatment outcomes between a short-term anticoagulation group (treated with LMWH for 10 days) and a compression group. There was no difference in the thrombus propagation rate (3.7% in LMWH group vs. 3.8% in compression group) and there was no clinical PE and no death.
Another issue in ICVT is post-thrombotic syndrome. In several studies, long-term symptoms and significant hemodynamic changes occur after ICVT [21] [22] [23] . Browse et al. [21] reported a 20% incidence of moderate to severe postphlebitic symptoms and signs 5 to 10 years after symptomatic ICVT. Meissner et al. [22] reported that 23% of patients with ICVT showed persistent symptoms and the development of valvular incompetence at 1 year, although recanalization proceeded rapidly. In a populationbased study [23] , the cumulative incidence of post-thrombotic syndrome after ICVT was 10.2%, 22%, and 29.8% at 2 years, 10 years, and 20 years respectively.
We preferred 3-month oral anticoagulation therapy for patients with ICVT if a patient had a concomitant PE at initial diagnosis. On follow-up DVT-CT 3 to 6 months after the first diagnosis of ICVT, thrombus propagation was not detected and all ICVTs resolved regardless of treatment.
And, there was no newly developed PE in the conservative treatment group. This result suggests that 3-month oral anticoagulation therapy for ICVT patients without PE after TKA may not be necessary concerning the risk of proximal thrombus propagation and development of PE. It is assumed that most postoperative ICVT resolve spontaneously when the postoperative period passes and the patients can ambulate because TKA is a transient risk factor
for VTE.
The limitation of this study is that it is a retrospective design with no randomization. Further, long-term followup is necessary to evaluate disease recurrence and postthrombotic syndrome. Indeed, to establish a consensus guideline for ICVT treatment, a large-scale prospective randomized study is necessary.
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